Lifestyle among long-term survivors of cancers in young adulthood

Synne-Kristin H. Bøhn \(^1\) · Hanne C. Lie \(^1,2\) · Kristin V. Reinertsen \(^1\) · Sophie D. Fosså \(^1,3\) · Hege S. Haugnes \(^4,5\) · Cecilie E. Kiserud \(^1\) · Jon Håvard Loge \(^2,6\) · Torbjørn Wisløff \(^7,8\) · Lene Thorsen \(^1,9\)

Received: 19 November 2019 / Accepted: 27 March 2020 / Published online: 1 May 2020
© The Author(s) 2020

Abstract

Purpose To investigate lifestyle in a population-based sample of long-term (≥ 5 years since diagnosis) young adult cancer survivors (YACs), and explore factors associated with not meeting the lifestyle guidelines for physical activity (PA), body mass index (BMI), and smoking.

Methods YACs \((n = 3558)\) diagnosed with breast cancer (BC), colorectal cancer (CRC), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), or localized malignant melanoma (MM) between the ages of 19 and 39 years and treated between 1985 and 2009 were invited to complete a mailed questionnaire. Survivors of localized MM treated with limited skin surgery served as a reference group for treatment burden.

Results In total, 1488 YACs responded (42%), and 1056 YACs were evaluable and included in the present study (74% females, average age at survey 49 years, average 15 years since diagnosis). Forty-four percent did not meet PA guidelines, 50% reported BMI \(≥ 25\) and 20% smoked, with no statistically significant differences across diagnostic groups. Male gender, education \(≤ 13\) years, comorbidity, lymphedema, pain, chronic fatigue, and depressive symptoms were associated with not meeting single and/or an increasing number of lifestyle guidelines.

Conclusion A large proportion of long-term YACs do not meet the lifestyle guidelines for PA, BMI, and/or smoking. Non-adherence to guidelines is associated with several late effects and/or comorbidities that should be considered when designing lifestyle interventions for YACs.

Keywords Late effects · Unhealthy lifestyle · Physical activity · Overweight · Smoking
Introduction

Each year, approximately 130,000 individuals aged 20 to 39 years are diagnosed with cancer in Europe [1]. Improvements in detection and treatment have led to a relative 5-year survival rate of more than 80%, thus creating a rapidly growing population of long-term (≥5 years since diagnosis) young adult cancer survivors (YACSs) [2, 3]. Their life-saving treatment, however, places long-term YACSs at risk of late effects, such as fatigue, cardiovascular diseases, and second cancer [3–5].

Physical activity (PA), a healthy body mass index (BMI), and non-smoking are associated with a lower risk of cancer recurrence, morbidity, and mortality [6–8], and are considered key components to improve and preserve long-term health among cancer survivors [9]. Furthermore, healthy lifestyle behaviors (and conversely, unhealthy behaviors) are likely to cluster within individuals, e.g., those who are physically active are likely to not smoke [10]. Meeting several lifestyle guidelines provides superior health benefits compared with meeting only a single guideline [9]. Similar to the population in general, cancer survivors are therefore recommended to be physically active for at least 150 min with moderate intensity or 75 min with high intensity per week, maintain a healthy BMI, avoid smoking, and consume at least five daily servings of vegetables and fruits (“5-a-day”) [11, 12].

Despite the well-known health benefits of meeting these guidelines, a large proportion of cancer survivors are physically inactive, overweight and do not meet “5-a-day”, and few cancer survivors meet multiple lifestyle guidelines (7–40%) [10, 13]. To date, research on lifestyle in cancer survivors is predominantly based on populations diagnosed with cancer after the age of 50, examined less than 5 years since diagnosis [10, 13]. Although a cancer diagnosis may immediately motivate individuals to live a more healthy life [9], little is known about the lifestyle of those surviving 5 years and beyond.

The few studies which have investigated lifestyle in YACSs have also mostly included populations less than 5 years since diagnosis [14–16]. Two recent studies from the USA investigated lifestyle exclusively among long-term adolescent and YACSs, and found that 56–65% were not meeting the PA guidelines, and one in three were smoking [17, 18]. Generalizability of these US findings to European long-term YACS is, however, questionable due to differences in culture and health care systems.

For long-term YACSs, empirical knowledge on their lifestyle is lacking. To our knowledge, no previous studies have investigated the adherence to multiple lifestyle guidelines in long-term YACSs. Demographic characteristics, such as male gender, older age, and low education have been linked to unhealthy lifestyle behaviors among survivors diagnosed with cancer at a young age [19], but associations between lifestyle and cancer treatments and late effects, as well as other health characteristics, are scarcely explored in long-term YACSs. One might hypothesize that some groups of long-term YACSs might be more susceptible to an unhealthy lifestyle than others, e.g., a high treatment burden with subsequent late effects such as fatigue might limit individuals in meeting the PA guidelines. Knowledge on demographic, cancer-related, and health characteristics of those with an unhealthy lifestyle is required in order to identify subgroups that might need particular support, and to develop effective lifestyle interventions for long-term YACSs [15, 16].

On this background, the overall aim of the present study was to investigate lifestyle among long-term YACSs, based on data from a large population-based cross-sectional survey named The Norwegian childhood, adolescent, and young adult cancer survivor study (The NOR-CAYACS study) [20]. Specific aims were to:

1) Investigate the adherence to lifestyle guidelines among Norwegian long-term YACSs treated for breast cancer (BC), colorectal cancer (CRC), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), or localized malignant melanoma (MM).

2) Explore demographic, cancer-related, and health characteristics associated with not meeting single and an increasing number of guidelines for PA, BMI, and smoking.

Based on existing knowledge about lifestyle in other populations of cancer survivors, we hypothesized that most YACSs would not meet PA guidelines and/or be overweight, but that a minority would be smoking. Moreover, we hypothesized that low level of education, comorbid conditions, and late effects would be associated with not meeting lifestyle guidelines.

Methods

Design and study population

Details on study design and population have been described previously [20]. In brief, 3558 YACSs diagnosed with BC, CRC, NHL, or ALL, as well as a randomly selected subsample of MM, between the ages of 19 and 39 years during 1985–2009 were identified by the Cancer Registry of Norway (CRN), and invited to participate in a postal questionnaire-based survey. The selection of the cancer diagnoses was based on their relative frequent occurrence during young adulthood, on the good prognosis and the relatively high risk of late effects. YACSs of other relevant cancer types such as testicular cancer, Hodgkin lymphoma, and cervical cancer were not invited because survivors after these diagnoses already participated in other ongoing studies at our research unit at the time.
Variables and measurements

Lifestyle

Physical inactivity was defined as not meeting the guidelines of ≥150 min of moderate intensity PA or 75 min high intensity PA, or an equivalent combination of moderate and high intensity PA per week [11], using a modified version of the Godin Leisure Time Exercise Questionnaire (GLTEQ) [21]. The GLTEQ assesses the average frequency and number of minutes of mild, moderate, and vigorous leisure time PA during a typical week. The number of minutes within the different intensity levels of PA were calculated for each participant, and used to classify individuals as physically active (≥150 min of moderate intensity or ≥75 min of vigorous intensity per week) or inactive according to the PA guidelines.

BMI (kg/m²) was calculated from self-reported height and body weight, and categorized according to the World Health Organization’s categorization of BMI in adults, healthy weight (18.5–24.9 kg/m²), and overweight/obese (>25.0–29.9 kg/m²) and obese (≥30 kg/m²) [22].

“5-a-day” was assessed by a question modified from the Nord-Trøndelag Health (HUNT) study [23], asking the participants how often they consume at least five daily servings of vegetables, fruits, and berries. Responses were categorized into meeting “5-a-day” (every day) and not meeting “5-a-day” (4–6 days per week/1–3 days per week/less than 1 day per week). Nutrition guidelines are complex, and for this paper, we chose to only include the measure on “5-a-day,” which has shown to be associated with other healthy eating habits [24].

Current smoking was assessed by the question “Do you smoke?”, from the HUNT study [23]. Responses were dichotomized into yes (smoking daily or smoking now and then) versus no (discontinued smoking/never smoked).

A more unhealthy lifestyle: the number of lifestyle guidelines not met (physically inactive, BMI ≥25 and smoking) were summed for each participant (0 to 3). Because of the large proportion not meeting “5-a-day” (92%), “5-a-day” was not included in the score of a more unhealthy lifestyle.

Explanatory variables

Participants self-reported on demographic, cancer treatment, and health variables, while information on cancer type and initial stage was obtained from the CRN.

Living with a partner included marriage and cohabitation. Education level was dichotomized into ≤13 years (up to high school) versus >13 years (college/university).

Treatment intensity was categorized as (1) limited surgery for localized MM (surgical removal of the skin lesion), (2) surgery and/or radiotherapy, (3) systemic treatment only, and (4) systemic treatment combined with surgery and/or radiotherapy.

Number of comorbid conditions was assessed using a modified version of the Charlson comorbidity index [25]. For each participant, the number of the following comorbid conditions...
ever experienced was summed and categorized as “no comorbidit-
ity,” “1–2 comorbid conditions,” and “> 2 comorbid condi-
tions”: cardiovascular and pulmonary diseases, diabetes, kid-
ey disease, gastro-intestinal disease, rheumatic disease, ar-
throsis, muscle/joint pain, epilepsy, and thyroid diseases.

Presence of numbness in hands/feet and lymphedema were
categorized as yes/no. Pain was assessed by the pain item in
the 12-Item Short Form Survey (SF-12) [26]. Responses were
dichotomized as no (“not at all”/“a little bit”/“moderately”)
versus yes (“quite a bit”/“extremely”). Using questions modified
from the HUNT study [23], trouble sleeping was defined as
experiencing one or more of the following three problems
several times per week: “difficulties falling asleep at night,”
“waking up repeatedly during the night,” and/or “waking up
too early without being able to go back to sleep.”

Depressive symptoms were assessed using the nine-item
Patient Health Questionnaire-9 (PHQ-9), which corresponds
to the Diagnostic and Statistical Manual of Mental Disorders
diagnostic criteria for major depressive disorders [27]. The
PHQ-9 contains 9 items. The frequency of experienced de-
pressive symptoms during the last 2 weeks with response cat-
egories ranging from 0 (not at all) to 3 (nearly every day) is
assessed. Increasing sum score (0 to 27) indicates higher level
of depressive symptoms. Anxiety symptoms were measured by
the seven-item anxiety subscale of The Hospital Anxiety and
Depression Scale (HADS-A) [28], with response categories
from 0 (not present) to 3 (highly present). An increasing
sum score (0 to 21) indicates higher level of anxiety symp-
toms. Cronbach’s alphas were 0.87 for PHQ-9 and 0.83 for
HADS-A in the present study population. HADS-A was used
to assess level of anxiety symptoms.

Chronic fatigue was assessed by the Fatigue Questionnaire
(FQ) [29]. FQ contains 11 items distributed on two subscales:
physical fatigue (7 items) and mental fatigue (4 items). Each
item is scored from 0 to 3, with increasing total score (0 to 33)
implying higher levels of fatigue. To identify chronic fatigue,
raw scores of each item were dichotomized (0 = 0, 1 = 0, 2 = 1,
3 = 1). Chronic fatigue was defined by a dichotomized sum
score ≥ 4 and ≥ 6 months duration of fatigue [29]. Cronbach’s
alphas for the present study population were 0.91 (physical
subscale), 0.84 (mental subscale), and 0.92 (the whole scale).

Statistical analyses

Continuous variables were described using mean and standard
deviation (SD), and categorical variables were presented as
numbers and percentages. Comparisons across diagnostic
groups were performed with chi-square tests or one-way anal-
ysis of variance. Logistic regression analyses identified factors
associated with not meeting single guidelines of PA, over-
weight, and smoking. Ordinal regression analyses were ap-
plied to identify factors associated with an increasing number
of unhealthy lifestyle factors in terms of physical inactivity,
overweight, and smoking (0 to 3), referred to as a more un-
healthy lifestyle. Variables statistically significant associated
with the dependent variable in unadjusted analyses (p < 0.05)
were included as independent variables in the multivariable
regression analyses. Limited surgery for localized MM was
used as a reference group for treatment burden in the regres-
sion analyses.

All independent variables included in multivariable analy-
ses were checked for multicollinearity, and all correlation
coefficients were < 0.8). Because of overlapping content in
the items in FQ and PHQ-9, only chronic fatigue was included
in multivariable analyses if both fatigue and depressive symp-
toms were statistically significant associated with the depen-
dent variable in unadjusted analyses. For the ordinal regres-
sion analyses, the proportional odds assumption was con-
firmed by the test of parallel lines. Results from the multivar-
iable analyses were presented as adjusted odds ratios (aOR)
with 95% confidence intervals (95% CI). P values < 0.05 were
considered statistically significant. Statistical analyses were
performed using IBM SPSS statistics version 25.0.

Compliance with ethical standards

The NOR-CAYACS study was approved by the South East
Regional Committee for Medical and Health Research Ethics
(no: 2015/232), the Norwegian Data Protection Authority (no:
15/00395-2/CGN), the Data Protection Officer at Oslo
University Hospital and the CRN. Informed consent was ob-
tained from all individual participants included in the study.
The authors declare that they have no conflict of interest.

Results

Characteristics of participants

A total of 1488 (42%) YACSs responded. After exclusion of
432 responders, 1056 evaluable participants were retained
(Fig. 1). Characteristics of evaluable responders versus non-
responders are described in the online resource file.

Characteristics of the sample are presented in Table 1. In
brief, 74% were female, 40% diagnosed with BC, 11% CRC,
16% NHL, 10% ALL, and 23% MM. Mean age at survey was
49.0 years (SD 7.7), and mean time since diagnosis was
15.2 years (SD 6.8). Forty-seven percent of the participants
were current smokers, and 92% did not smoke (0 to 3), re-
ferred to as a more unhealthy lifestyle. Variables statistically
significant associated with the dependent variable in unadjusted
analyses (p < 0.05) were included as independent variables in the multivariable
regression analyses. Limited surgery for localized MM was
used as a reference group for treatment burden in the regres-
sion analyses.

Adherence to lifestyle guidelines

Among all YACSs, 44% were physically inactive, 50% were
overweight, 20% were current smokers, and 92% did not

Springer
Table 1  Demographic, cancer-related, and health characteristics of the participants

| Variables                        | Total (n = 1056) |
|----------------------------------|------------------|
| Demographic variables            |                  |
| Female gender, n (%)             | 783 (74)         |
| Age at survey, mean (SD)         | 49.0 (7.7)       |
| Living with a partnerb, n (%)    | 841 (80)         |
| Living with childrenc, n (%)     | 415 (39)         |
| Education > 13 years, n (%)      | 624 (60)         |
| Cancer-related variables         |                  |
| Age at diagnosis, mean (SD)      | 32.8 (5.4)       |
| Years since diagnosis, mean (SD) | 15.2 (6.8)       |
| Cancer type, n (%)               |                  |
| Breast cancer                    | 422 (40)         |
| Colorectal cancer                | 116 (11)         |
| Non-Hodgkin lymphoma             | 167 (16)         |
| Acute lymphoblastic leukemia      | 105 (10)         |
| Malignant melanoma               | 246 (23)         |
| Treatment modality, n (%)        |                  |
| Limited surgery for localized malignant melanoma | 246 (23) |
| Surgery and/or radiotherapy       | 166 (16)         |
| Systemic treatment alone         | 144 (14)         |
| Systemic treatment combined with surgery and/or radiotherapy | 500 (47) |
| Health variables                 |                  |
| Number of comorbid conditions, n (%) |          |
| None                             | 292 (28)         |
| 1–2                              | 560 (53)         |
| >2                               | 202 (19)         |
| Numbness in hands/feet, n (%)    | 174 (18)         |
| Lymphedema, n (%)                | 213 (22)         |
| Paina, n (%)                     | 106 (10)         |
| Trouble sleepingb, n (%)         | 469 (44)         |
| PHQ-9 scorec, mean (SD)          | 5.3 (4.8)        |
| HADS-A scored, mean (SD)         | 4.7 (3.7)        |
| Chronic fatiguec, n (%)          | 257 (25)         |

SD, standard deviation

Missing data are as follows: living with a partner/with children n = 2; education level n = 8; comorbid conditions n = 2; numbness in hands/feet n = 79; lymphedema n = 63; pain n = 9; trouble sleeping n = 1; PHQ-9 n = 5; HADS-A n = 4; chronic fatigue n = 16

a Married or cohabitant
b Aged < 18 years
c College/university
d Defined as pain interfering quite a bit or extremely with normal work
e Experiencing difficulties falling asleep at night, waking up repeatedly during the night, and/or waking up too early without being able to go back to sleep several times per week
f The Patient Health Questionnaire-9, range 0–27. Increasing score implies higher level of depressive symptoms
g The Hospital Anxiety and Depression Scale, anxiety subscale, range 0–21. Increasing score implies higher level of anxiety
h Elevated fatigue symptoms of at least 6 months duration

Percentages may not add up to 100 because of rounding

Factors associated with not meeting lifestyle guidelines

Factors associated with physical inactivity, overweight, or smoking in unadjusted analyses are shown in Table 3.

In multivariable analyses, only chronic fatigue remained associated with physical inactivity (aOR 1.50, 95% CI 1.11–2.03) (Table 3). Male gender (aOR 2.50, 95% CI 1.80–3.45), >2 comorbid conditions (aOR 1.99, 95% CI 1.31–3.04), lymphedema (aOR 1.77, 95% CI 1.25–2.50), and increasing levels of depressive symptoms (aOR 1.03, 95% CI 1.01–1.06) were associated with being overweight. Systemic treatment combined with surgery and/or radiotherapy was negatively associated with overweight (aOR 62, 95% CI 0.44–0.89). Living without a partner (aOR 1.50, 95% CI 1.02–2.21), education ≤ 13 years (aOR 1.63, 95% CI 1.18–2.27) and lymphedema (aOR 1.67, 95% CI 1.15–2.41) were positively associated with smoking (Table 3).

Factors associated with a more unhealthy lifestyle in unadjusted analyses are shown in Table 4. Male gender (aOR 1.80, 95% CI 1.37–2.37), education ≤ 13 years (aOR 1.44, 95% CI 1.13–1.84), >2 comorbid conditions (aOR 1.57, 95% CI 1.08–2.29), lymphedema (aOR 1.37, 95% CI 1.02–1.84), and pain (aOR 1.54, 95% CI 1.0–2.35) were associated with a more unhealthy lifestyle in multivariable ordinal regression analyses.

Discussion

This large population-based study on lifestyle among long-term YACSs shows that the majority of long-term YACSs are physically inactive, overweight, and/or not meeting “5-a-day,” and that one in five are smokers. Only one in four YACSs meet the combination of PA, BMI, and smoking guidelines. Non-adherence to lifestyle guidelines is associated with male gender, living without a partner, education ≤ 13 years, comorbid conditions, lymphedema, pain, increasing levels of depressive symptoms, and/or chronic fatigue.

Importantly, the diversity of measures, population characteristics, and cultural differences across studies limit direct comparison of our findings with previous results on lifestyle among cancer survivors. Taking this into account, long-term YACSs shows that the majority of long-term YACSs are physically inactive, overweight, and/or not meeting “5-a-day,” and that one in five are smokers. Only one in four YACSs meet the combination of PA, BMI, and smoking guidelines. Non-adherence to lifestyle guidelines is associated with male gender, living without a partner, education ≤ 13 years, comorbid conditions, lymphedema, pain, increasing levels of depressive symptoms, and/or chronic fatigue.

Factors associated with physical inactivity, overweight, or smoking in unadjusted analyses are shown in Table 3.

In multivariable analyses, only chronic fatigue remained associated with physical inactivity (aOR 1.50, 95% CI 1.11–2.03) (Table 3). Male gender (aOR 2.50, 95% CI 1.80–3.45), >2 comorbid conditions (aOR 1.99, 95% CI 1.31–3.04), lymphedema (aOR 1.77, 95% CI 1.25–2.50), and increasing levels of depressive symptoms (aOR 1.03, 95% CI 1.01–1.06) were associated with being overweight. Systemic treatment combined with surgery and/or radiotherapy was negatively associated with overweight (aOR 62, 95% CI 0.44–0.89). Living without a partner (aOR 1.50, 95% CI 1.02–2.21), education ≤ 13 years (aOR 1.63, 95% CI 1.18–2.27) and lymphedema (aOR 1.67, 95% CI 1.15–2.41) were positively associated with smoking (Table 3).

Factors associated with a more unhealthy lifestyle in unadjusted analyses are shown in Table 4. Male gender (aOR 1.80, 95% CI 1.37–2.37), education ≤ 13 years (aOR 1.44, 95% CI 1.13–1.84), >2 comorbid conditions (aOR 1.57, 95% CI 1.08–2.29), lymphedema (aOR 1.37, 95% CI 1.02–1.84), and pain (aOR 1.54, 95% CI 1.0–2.35) were associated with a more unhealthy lifestyle in multivariable ordinal regression analyses.
among Canadian YACSs of various cancer types diagnosed between the ages of 20 to 44 years. However, most of these participants were not long-term survivors (i.e., < 5 years since diagnosis).

The prevalence of overweight in our study (50%) is also in agreement with findings in Bélanger et al.’s study (53%) [15], and with findings in US survivors of BC and CRC diagnosed before the age of 50 and examined almost 10 years after diagnosis (55%) [31]. Higher proportions of overweight have been found among survivors diagnosed with cancer further into adulthood (60–75%) [13, 30].

Lower proportions of overweight have been reported among female adolescent survivors and YACSs in US studies (≈ 30%) [17, 18], but higher than found among older adult cancer survivors and the YACSs in the study by Bélanger et al. (13%) [13, 15].

Our results are also similar to the self-reported prevalence of overweight (48%) and smoking (women 17%, men 22%) in the general Norwegian population, while the proportion of physically inactive individuals in the general population (33%) is somewhat lower than among the YACSs (44%) [32, 33].

Furthermore, 92% of the participants in our study did not meet “5-a-day,” which is congruent with findings among the adolescent and YACSs in the study by Warner et al. [17] (up to 89% not meeting “5-a-day”) and the general Norwegian population (86%) [34]. In other populations of cancer survivors, somewhat higher proportions of survivors eating “5-a-day” have been reported (30–45%) [31, 35]. Given that close to all participants in our sample were not meeting “5-a-day,” we chose to not explore associated factors. A broader exploration of nutrition, e.g., guidelines on red meat, fish, sodium, and added sugar, would probably provide more information about the characteristics of long-term YACSs not meeting nutrition guidelines.

Assuming that long-term YACSs are aware of their risk for late effects following treatment, one could expect that they would be more motivated for having a healthy lifestyle than the general population. Due to their low treatment burden, one might hypothesize that survivors of localized MM would be more comparable to the population in general than to YACSs with a higher cancer treatment burden. However, adherence to lifestyle guidelines did not differ across the diagnostic groups in our study.

In sum, our findings suggest that despite their increased risk of a poorer health, long-term YACSs do not seem more likely of having a healthy lifestyle than the general population. One explanation for this might be lack of knowledge about the importance of a healthy lifestyle and their risk of late effects. In Norway, systemic follow-up programs including information on lifestyle issues for cancer survivors are lacking. Previous research has demonstrated limited knowledge about late effects among both cancer survivors [36] and general practitioners (GPs) [37]. Furthermore, in a recent systematic review, Tollosa et al. found that survivors 5 years or less from diagnosis had better health behavior than long-term survivors [13], suggesting that it is challenging to maintain a healthy lifestyle after cancer as time goes by. Moreover, as some late effects appear several years after treatment, cancer survivors might not be motivated for a healthy lifestyle until potential health problems occur. To the contrary, poor health and late

### Table 2 Adherence to lifestyle guidelines by cancer type

| Variables | Total | BC | CRC | NHL | ALL | MM | p value |
|-----------|-------|----|-----|-----|-----|----|---------|
| n = 1056  | n = 422 | n = 116 | n = 167 | n = 105 | n = 246 |
| Physically inactivea | 460 (44) | 175 (42) | 50 (43) | 69 (41) | 55 (52) | 111 (45) | 0.323 |
| BMI ≥ 25  | 528 (50) | 187 (44) | 62 (53) | 90 (54) | 58 (55) | 131 (53) | 0.056 |
| Current smoker | 165 (20) | 92 (22) | 22 (19) | 32 (19) | 19 (18) | 43 (18) | 0.702 |
| Not meeting 5-a-dayb | 744 (92) | 381 (91) | 106 (91) | 156 (93) | 101 (97) | 221 (91) | 0.226 |
| Number of lifestyle guidelines metc | 0 | 57 (5) | 22 (5) | 3 (3) | 10 (6) | 13 (12) | 9 (4) |
| 1 | 296 (28) | 110 (26) | 35 (30) | 45 (26) | 27 (26) | 79 (32) |
| 2 | 433 (41) | 168 (40) | 55 (47) | 71 (43) | 39 (37) | 100 (41) |
| 3 | 270 (26) | 122 (29) | 23 (20) | 41 (25) | 26 (25) | 58 (24) |

**BC,** breast cancer; **CRC,** colorectal cancer; **NHL,** non-Hodgkin lymphoma; **ALL,** acute lymphoblastic leukemia; **BMI,** body mass index (kg/m²)

a Defined as not meeting physical activity guidelines of at least 150 min moderate exercise per week or 75 min of high-intensity exercise or an equivalent combination

b Defined as consuming at least five daily servings of fruits and vegetables

c Including guidelines for physical activity, BMI, and smoking

Percentages may not add up to 100 because of rounding

294 Support Care Cancer (2021) 29:289–300
Table 3 Characteristics of physically inactive, overweight, and currently smoking participants and factors associated with these behaviors

| Variables                      | Physical inactivity<sup>a</sup> | Overweight (BMI ≥ 25 kg/m<sup>2</sup>) | Current smoking (daily or now and then) |
|--------------------------------|---------------------------------|----------------------------------------|----------------------------------------|
|                                | Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted |
|                                | cOR 95% CI | aOR 95% CI | p          | cOR 95% CI | aOR 95% CI | p          | cOR 95% CI | aOR 95% CI | p          | cOR 95% CI | aOR 95% CI | p          |
| Socio-demographic variables    |            |          |            |            |            |            |            |            |            |            |            |
| Sex, n (%)                     |            |          |            |            |            |            |            |            |            |            |            |
| Female (ref.)                  | 340 (43)   | 1.0      |            | 348 (44)   | 1.0        |            | 163 (21)   | 1.0        |            |            |            |
| Male                           | 120 (44)   | 1.02     | 0.77–1.35  | 180 (66)   | 2.42       | 1.82–3.22***| 2.50       | 1.80–3.45 < 0.001| 45 (17) | 0.75 0.52–1.08 |
| Age at survey, mean (SD)       | 48.2 (8.0) | 0.99     | 0.98–1.01  | 49.4 (7.5) | 1.01       | 0.99–1.03  | 49.4 (7.0) | 1.01       | 0.99–1.03  |            |            |
| Living with a partner, n (%)   |            |          |            |            |            |            |            |            |            |            |            |
| Yes (ref.)                     | 359 (43)   | 1.0      |            | 428 (51)   | 1.0        |            | 149 (18)   | 1.0        |            |            |            |
| No                             | 101 (47)   | 1.21     | 0.90–1.64  | 99 (47)    | 0.84       | 0.62–1.13  | 58 (27)    | 1.74       | 1.23–2.47**| 1.50       | 1.02–2.21 0.041|
| Living with children < 18 years, n (%) |            |          |            |            |            |            |            |            |            |            |            |
| Yes (ref.)                     | 169 (41)   | 1.0      |            | 192 (46)   | 1.0        |            | 69 (17)    | 1.0        |            |            |            |
| No                             | 291 (46)   | 1.22     | 0.95–1.56  | 335 (52)   | 1.28       | 0.99–1.64  | 138 (22)   | 1.38       | 1.0–1.90* | 1.10       | 0.78–1.54 0.604|
| Education level                |            |          |            |            |            |            |            |            |            |            |            |
| > 13 years (ref.)              | 253 (41)   | 1.0      |            | 295 (47)   | 1.0        |            | 98 (16)    | 1.0        |            |            |            |
| ≤ 13 years                     | 203 (48)   | 1.35     | 1.05–1.73* | 227 (54)   | 1.29       | 1.0–1.65* | 108 (26)   | 1.83       | 1.35–2.49***| 1.63       | 1.18–2.27 0.003|
| Cancer-related variables       |            |          |            |            |            |            |            |            |            |            |            |
| Years since diagnosis, mean (SD) | 15.5 (7.0) | 1.01     | 0.99–1.03  | 15.5 (6.8) | 1.01       | 0.99–1.03  | 15.4 (6.8) | 1.01       | 0.98–1.03  |            |            |
| Treatment modality, n (%)      |            |          |            |            |            |            |            |            |            |            |            |
| Reference<sup>b</sup>          | 111 (45)   | 1.0      |            | 131 (53)   | 1.0        |            | 43 (18)    | 1.0        |            |            |            |
| Surgery and/or radiotherapy    | 76 (46)    | 1.03     | 0.69–1.53  | 88 (53)    | 0.99       | 0.67–1.47  | 27 (16)    | 0.92       | 0.54–1.55  |            |            |
| Systemic treatment alone       | 72 (50)    | 1.22     | 0.81–1.84  | 83 (58)    | 1.19       | 0.79–1.81  | 30 (21)    | 1.24       | 0.74–2.09  |            |            |
| Systemic treatment with surgery and/or radiotherapy | 201 (40) | 0.82 | 0.60–1.11 | 226 (45) | 0.72 | 0.53–0.98* | 0.62 | 0.44–0.89 | 0.009 | 108 (22) | 1.30 | 0.88–1.93 |
| Health variables, n (%)        |            |          |            |            |            |            |            |            |            |            |            |
| Number of comorbid conditions  |            |          |            |            |            |            |            |            |            |            |            |
| None (ref.)                    | 116 (40)   | 1.0      |            | 131 (45)   | 1.0        |            | 53 (18)    | 1.0        |            |            |            |
| 1–2                            | 237 (42)   | 1.11     | 0.84–1.49  | 0.93       | 0.69–1.26  | 0.637      | 267 (48)   | 1.12       | 0.84–1.49  | 0.99       | 0.73–1.35 0.948|
| > 2                            | 105 (52)   | 1.64     | 1.14–2.36**| 1.19       | 0.80–1.76  | 0.390      | 130 (64)   | 2.22       | 1.53–3.21***| 1.99       | 1.31–3.04 0.001|

<sup>a</sup> Adjusted for all other variables. <sup>b</sup> Reference category for treatment modality.
### Table 3 (continued)

| Variables                  | Physical inactivity<sup>a</sup> | Overweight (BMI ≥ 25 kg/m²) | Current smoking (daily or now and then) |
|----------------------------|---------------------------------|-----------------------------|-----------------------------------------|
|                            | Unadjusted                      | Adjusted                   | Unadjusted                      | Adjusted                   | Unadjusted                      | Adjusted                   |
|                            | cOR 95% CI                      | aOR 95% CI                 | p                           | cOR 95% CI                  | aOR 95% CI                  | p                           | cOR 95% CI                  | aOR 95% CI                  | p                           |
| Numbness in hands/feet     |                                 |                             |                             |                             |                             |                             |                             |                             |                             |
| No (ref.)                  | 352 (44)                        | 1.0                         |                             | 1.0                         |                             |                             | 1.0                         |                             |                             |
| Yes                        | 81 (47)                         | 1.12                        | 0.80–1.55                   | 83 (48)                     | 0.93                        | 0.67–1.29                   | 1.17                        | 0.78–1.75                   | 37 (21)                     | 1.0                         | 0.78–1.75                   |
| Lymphedema                 |                                 |                             |                             |                             |                             |                             |                             |                             |                             |
| No (ref.)                  | 342 (44)                        | 1.0                         |                             | 1.0                         |                             |                             | 1.0                         |                             |                             |
| Yes                        | 94 (44)                         | 1.01                        | 0.75–1.37                   | 121 (57)                    | 1.44                        | 1.06–1.96                   | 1.77                        | 1.25–2.50                   | 0.001                       | 1.0                         | 1.0                         |
| Pain interfering with normal work |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| No (ref.)                  | 393 (42)                        | 1.0                         |                             | 1.0                         |                             |                             | 1.0                         |                             |                             |
| Yes                        | 61 (58)                         | 1.89                        | 1.26–2.84**                 | 1.39                        | 0.89–2.16                   | 1.0                         | 1.39                        | 0.89–2.16                   | 1.0                         | 1.39                        | 0.89–2.16                   |
| Trouble sleeping           |                                 |                             |                             |                             |                             |                             |                             |                             |                             |
| No (ref.)                  | 233 (40)                        | 1.0                         |                             | 1.0                         |                             |                             | 1.0                         |                             |                             |
| Yes                        | 227 (48)                        | 1.42                        | 1.11–1.82**                 | 1.24                        | 0.95–1.61                   | 0.114                       | 1.24                        | 0.95–1.61                   | 0.114                       | 1.24                        | 0.95–1.61                   |
| PHQ-9 score<sup>c</sup>, mean (SD) | 6.1 (5.1)                   | 1.07                        | 1.04–1.10***                | 6.1 (5.1)                   | 1.04                        | 1.01–1.06**                 | 6.1 (5.1)                   | 1.04                        | 1.01–1.06**                 | 6.1 (5.1)                   | 1.04                        | 1.01–1.06**                 |
| HADS-A score<sup>d</sup>, mean (SD) | 4.8 (3.8)                   | 1.02                        | 0.99–1.06                   | 4.7 (3.8)                   | 1.01                        | 0.98–1.04                   | 4.7 (3.8)                   | 1.01                        | 0.98–1.04                   | 4.7 (3.8)                   | 1.01                        | 0.98–1.04                   |
| Chronic fatigue<sup>e</sup>, n (%) |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| No (ref.)                  | 314 (40)                        | 1.0                         |                             | 1.0                         |                             |                             | 1.0                         |                             |                             |
| Yes                        | 138 (54)                        | 1.73                        | 1.30–2.30***                | 1.50                        | 1.11–2.03                   | 0.009                       | 1.50                        | 1.11–2.03                   | 0.009                       | 1.50                        | 1.11–2.03                   |

BMI, body mass index; 95% CI, 95% confidence interval; SD, standard deviation; cOR, crude odds ratio; aOR, adjusted odds ratio; Ref, reference

Italics: statistically significant result (p < 0.05)

Numbers included in adjusted multivariable analyses were 1024 for physically inactive, 981 for overweight, and 985 for smoking

<sup>a</sup> Physical inactivity was defined as not meeting physical activity guidelines of at least 150 min moderate or 75 min vigorous physical activity per week

<sup>b</sup> Limited skin surgery for malignant melanoma

<sup>c</sup> The Patient Health Questionnaire-9, range 0–27. Increasing score implies higher level of depressive symptoms

<sup>d</sup> The Hospital Anxiety and Depression Scale, anxiety subscale, range 0–21. Increasing score implies higher level of anxiety

<sup>e</sup> Defined as elevated level of fatigue of at least 6 months duration

<sup>f</sup> Not included in multivariable analyses due to overlap with chronic fatigue

*<sup>p</sup> < 0.05

**<sup>p</sup> < 0.01

***<sup>p</sup> < 0.001
effects after cancer may also limit the ability to obtain or maintain a healthy lifestyle [38].

Lifestyle interventions in cancer survivors must be targeted towards their unique needs and challenges [9]. We found that chronic fatigue was associated with not meeting PA guidelines, which is in line with previous research on fatigue and PA in survivors of lymphoma [39], CRC [40] and BC [41]. Fatigue is also one of the most commonly reported barriers for

Table 4  Ordinal logistic regression analyses of potential associated factors with not meeting multiple lifestyle guidelines*

|                           | Unadjusted |         |         |         | Adjusted** |         |         |
|---------------------------|------------|---------|---------|---------|------------|---------|---------|
|                           | cOR        | 95% CI  | p       | aOR     | 95% CI     | p       | 95% CI  |
| Sex, n (%)                |            |         |         |         |            |         |         |
| Female (ref.)             | 1.0        |         |         | 1.0     |            |         |         |
| Male                      | 1.46       | 1.14–1.88 | 0.003 | 1.80    | 1.37–2.37 | < 0.001|
| Age at survey, mean (SD)  | 1.01       | 0.99–1.02 | 0.306 |         |            |         |         |
| Living with a partner, n (%) | 1.0        |         |         | 1.0     |            |         |         |
| Yes (ref.)                |            |         |         |         |            |         |         |
| No                        | 1.26       | 0.96–1.66 | 0.100 |         |            |         |         |
| Living with children < 18 years, n (%) | 1.0 |         |         | 1.0     |            |         |         |
| Yes (ref)                 |            |         |         |         |            |         |         |
| No                        | 1.43       | 1.14–1.80 | 0.002 | 1.21    | 0.94–1.54 | 0.137  |
| Education level, n (%)    |            |         |         |         |            |         |         |
| > 13 years (ref.)         | 1.0        |         |         | 1.0     |            |         |         |
| ≤ 13 years                | 1.65       | 1.31–2.07 | < 0.001| 1.44    | 1.13–1.84 | 0.003  |
| Cancer-related variables  |            |         |         |         |            |         |         |
| Years since diagnosis, mean (SD) | 1.01      | 0.99–1.03 | 0.110 |         |            |         |         |
| Treatment modality, n (%) |            |         |         |         |            |         |         |
| Reference^                | 1.0        |         |         | 1.0     |            |         |         |
| Surgery and/or radiotherapy | 0.99    | 0.70–1.43 | 0.987 |         |            |         |         |
| Systemic treatment alone  | 1.24       | 0.85–1.80 | 0.269 |         |            |         |         |
| Systemic treatment with surgery and/or radiotherapy | 0.80 | 0.61–1.06 | 0.120 |         |            |         |         |
| Health variables          |            |         |         |         |            |         |         |
| Number of comorbid conditions, n (%) | 1.0 |         |         | 1.0     |            |         |         |
| None (ref.)               |            |         |         |         |            |         |         |
| 1–2                       | 1.11       | 0.86–1.44 | 0.435 | 0.94    | 0.71–1.24 | 0.641  |
| > 2                       | 2.17       | 1.16–3.03 | < 0.001| 1.57    | 1.08–2.29 | 0.018  |
| Numbness in hands/feet, n (%) |              |         |         |         |            |         |         |
| No (ref.)                 | 1.0        |         |         | 1.0     |            |         |         |
| Yes                       | 1.05       | 0.78–1.41 | 0.764 |         |            |         |         |
| Lymphedema, n (%)         |            |         |         |         |            |         |         |
| No (ref.)                 | 1.0        |         |         | 1.0     |            |         |         |
| Yes                       | 1.46       | 1.10–1.93 | 0.008 | 1.37    | 1.02–1.84 | 0.037  |
| Pain interfering with normal work, n (%) | 1.0 |         |         | 1.0     |            |         |         |
| No (ref.)                 |            |         |         |         |            |         |         |
| Yes                       | 2.10       | 1.45–3.05 | < 0.001| 1.54    | 1.0–2.35 | 0.048  |
| Trouble sleeping, n (%)   |            |         |         |         |            |         |         |
| No (ref.)                 | 1.0        |         |         | 1.0     |            |         |         |
| Yes                       | 1.35       | 1.08–1.68 | 0.009 | 1.10    | 0.86–1.42 | 0.450  |
| PHQ-9 scoreb, mean (SD)   | 1.07       | 1.05–1.10 | < 0.001| 1.02    | 0.98–1.05 | 0.357  |
| HADS-A score^c, mean (SD) | 1.03       | 1.00–1.07 | 0.026 |         |            |         |         |
| Chronic fatigue^e, n (%)  |            |         |         |         |            |         |         |
| No (ref.)                 | 1.0        |         |         | 1.0     |            |         |         |
| Yes                       | 1.38       | 1.06–1.79 | 0.015 | 1.09    | 0.81–1.46 | 0.573  |

95% CI = 95% confidence interval; SD, standard deviation; cOR, crude odds ratio; aOR, adjusted odds ratio; Ref., reference. Variables associated (p < 0.05) (italics) with not meeting an increasing number of guidelines in unadjusted analyses were included as explanatory variables in the adjusted analyses.

^aNot meeting an increasing number of PA, BMI, and/or smoking guidelines

^bNumbers included in multivariable analyses were 968

^cLimited surgery for malignant melanoma

^dThe Patient Health Questionnaire-9

^eNot included in multivariable analyses due to overlap with chronic fatigue

^fThe Hospital Anxiety and Depression Scale, anxiety subscale

^gElevated fatigue symptoms of at least 6 months duration
PA among cancer survivors in general [38]. PA is, however, also recommended to improve fatigue among cancer survivors, as physical inactivity and subsequent loss of muscle mass and physical function may worsen fatigue symptoms [42].

Also in agreement with previous findings among cancer survivors in general, being overweight in the present study was associated with male gender [30], comorbid conditions [39], and depressive symptoms [19]. We found that long-term YACSs who had received multimodal therapy were less likely to be overweight than MM survivors treated with limited surgery. This is in line with the findings in a recent study by our group reporting that receipt of three or more treatment regimens was associated with a decreased risk of being overweight in long-term lymphoma survivors treated with high-dose chemotherapy with autologous stem cell support [39]. However, research in BC survivors has reported large variations in weight change (gain, maintenance, and loss) during and after adjuvant systemic treatments [43].

The finding that only one in four long-term YACSs met all guidelines with regard to PA, BMI, and non-smoking is comparable with the results in the study by Spector et al., showing that 20% of older long-term NHL survivors met these three guidelines [35]. Also congruent with our findings, Tollosa et al. estimated that 23% of adult cancer survivors met a combination of several lifestyle recommendations [13]. Considering their long life-expectancy with risk of late effects and future health challenges associated with aging, adhering to a combination of multiple lifestyle guidelines might be particularly important for YACSs.

Our findings indicate a need to inform YACSs and health personnel involved in the follow-up of YACSs about the benefits of a healthy lifestyle also as a preventive measure against late effects. Such information may be conveyed through courses for cancer survivors and health personnel involved in the follow-up care of cancer survivors, and by establishing guidelines for lifestyle advice as part of follow-up. Moreover, focus on lifestyle and long-term health should be implemented in individual care plans and patient information (brochures-electronically). Patients should receive information or counseling about the benefits of a healthy lifestyle in a manner tailored to their needs and health literacy levels.

The main strength of this study is the large national population-based sample of YACSs, which is an understudied population in terms of long-term cancer survivorship [44]. Our study contributes with new knowledge about lifestyle and its associations to late effects, assessed with established patient-reported outcome measures. Such measures are essential to capture patient perspectives and symptoms that are subjective in nature and may lack universal diagnostic criteria (e.g., fatigue) [45]. Limitations include the cross-sectional design precluding causal conclusions, and the reliance on self-reported treatment data. The response rate of 42% and the high proportion of females and BC survivors might increase the risk of bias. However, Lie et al. recently found low risk of non-response bias in the NOR-CAYACS study on a wide range of survey outcomes, including lifestyle [20].

**Conclusion**

Many long-term YACSs are not meeting one or more of the public guidelines for PA, BMI, and smoking. Health personnel involved in the follow-up of YACSs must have knowledge and focus on late effects and healthy lifestyle behaviors. YACSs with male gender, who are living without a partner, with education ≤ 13 years, comorbid conditions, lymphedema, pain, increasing levels of depressive symptoms, and/or chronic fatigue might have an increased risk of not meeting one or more of these guidelines. YACSs with these characteristics might need special attention to achieve and maintain a healthy lifestyle.

**Authors’ contributions** All authors contributed to the study conception and design, or acquisition of data. Data preparation and analysis were performed by Synne-Kristin Hoffart Bøhn. The first draft of the manuscript was written by Synne-Kristin Hoffart Bøhn, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding information** Open Access funding provided by University of Oslo (incl Oslo University Hospital). This work was supported by The Norwegian Cancer Society under Grant number 45980 and The Research Council of Norway under Grant number 218312.

**Data availability** The authors have full control of all primary data and the journal may review the data if requested.

**Compliance with ethical standards**

The NOR-CAYACS study was approved by the South East Regional Committee for Medical and Health Research Ethics (no. 2015/222), the Norwegian Data Protection Authority (no: 15/00395-2/CGN), the Data Protection Officer at Oslo University Hospital and the CRN. Informed consent was obtained from all individual participants included in the study.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
33. Hansen B, Anderssen SA, Steene-Johannessen J et al (2015) Fysisk aktivitet og sedent tid blant voksne og eldre i Norge - Nasjonal kartlegging 2014–2015. Helsedirektoratet, Oslo
34. Totland T, Melnæs BK, Lundberg-Hallén N et al (2012) En landsomfattende kostholdsundersøkelse blant menn og kvinner i Norge i alderen 18–70 år, 2010–11. Helsedirektoratet, Oslo
35. Spector DJ, Noonan D, Mayer DK, Benecha H, Zimmerman S, Smith SK (2015) Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma? Cancer 121(18):3343–3351. https://doi.org/10.1002/cncr.29490
36. Hess SL, Johannsdottir IM, Hamre H et al (2011) Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects. Acta Oncol (Stockholm, Sweden) 50(5):653–659. https://doi.org/10.3109/0284186x.2010.550934
37. Nekhlyudov L, Aziz NM, Lerro C, Virgo KS (2014) Oncologists’ and primary care physicians’ awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract 10(2):e29–e36. https://doi.org/10.1200/JOP.2013.001121
38. Clifford BK, Mizrahi D, Sandler CX, Barry BK, Simar D, Wakefield CE, Goldstein D (2018) Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. Support Care Cancer 26(3):685–700. https://doi.org/10.1007/s00520-017-3964-5
39. Bersvendsen HS, Haugnes HS, Fagerli UM et al. (2019) Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. Acta Oncol (Stockholm, Sweden) 1–10. https://doi.org/10.1080/0284186x.2018.1558370
40. van Putten M, Hussin O, Mols F, Luyer MDP, van de Poll-Franse L, Ezendam NPM (2016) Correlates of physical activity among colorectal cancer survivors: results from the longitudinal population-based profiles registry. Support Care Cancer 24(2):573–583. https://doi.org/10.1007/s00520-015-2816-4
41. Brunet J, Amireault S, Chaiton M, Sabiston CM (2014) Identification and prediction of physical activity trajectories in women treated for breast cancer. Ann Epidemiol 24(11):837–842. https://doi.org/10.1016/j.anneprev.2014.07.004
42. Lucia A, Earnest C, Perez M (2003) Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol 4(10):616–625
43. Nyrop KA, Williams GR, Muss HB, Shachar SS (2016) Weight gain during adjuvant endocrine treatment for early-stage breast cancer: what is the evidence? Breast Cancer Res Treat 158(2):203–217. https://doi.org/10.1007/s10549-016-3874-0
44. Sender L, Zabokrtsky KB (2015) Adolescent and young adult patients with cancer: a milieu of unique features. Nat Rev Clin Oncol 12:465–480. https://doi.org/10.1038/nrclinonc.2015.92
45. Reeve BB, Wyrrich KW, Wu AW et al. (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. 22(8):1889–1905. https://doi.org/10.1007/s11136-012-0344-y

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.